Resources for Food and Drug Administration (FDA)

F.D.A. Panel Votes to Keep Diabetes Drug on Market

www.nytimes.com

A federal drug advisory committee voted 20 to 3 late this afternoon that Avandia, a controversial diabetes drug made by GlaxoSmithKline, raises the risks of heart attacks, but it then voted 22 to 1 that the drug should nonetheless remain on the market.

The divided vote came after committee members said that studies concerning Avandia were too murky to merit drastic regulatory action and that other diabetes medicines might have similar risks.

View the Resource

Share or bookmarklet this web page at: